NEI November 1 - 2025 Supporting materials POSTER: Symptoms of Major Depressive Disorder in Adults That Potentially Benefit From the Digital Therapeutic CT-152 POSTER: Assessment of Efficacy Outcomes Based on Treatment Adherence to Rejoyn (CT-152) in Adults With Major Depressive Disorder POSTER: Effects of adjunctive brexpiprazole on depression and life engagement in patients with noradrenaline-mediated symptoms POSTER: Patient-reported symptom severity and functioning with brexpiprazole in combination with sertraline in adults with post-traumatic stress disorder POSTER: Efficacy of brexpiprazole in combination with sertraline on individual symptoms of post-traumatic stress disorder in adults POSTER: Adult Responders and Participant-Reported Depressive Symptom Clusters That May Benefit From CT-152 Therapy for Major Depressive Disorder POSTER: Evaluating Changes in Anxiety Symptoms With Rejoyn (CT-152) Among Adult Participants With Major Depressive Disorder and Comorbid Anxiety POSTER: A Prescription Digital Therapeutic, CT-152, for Treating Major Depressive Disorder: Effectiveness and Safety Results of the Mirai Randomized Controlled Trial POSTER: Efficacy of CT-152 for Major Depressive Disorder in Adult Participants With Baseline Anxiety Symptoms and/or Difficulty Sleeping
